These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 16815778)
1. The effects of impact and non-impact exercise on circulating markers of collagen remodelling in humans. Mackey AL; Donnelly AE; Swanton A; Murray F; Turpeenniemi-Hujanen T J Sports Sci; 2006 Aug; 24(8):843-8. PubMed ID: 16815778 [TBL] [Abstract][Full Text] [Related]
2. [Alterations of metalloproteinases and their inhibitors concentrations in peripheral blood in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass]. Paśnik J; Cywińska-Bernas A; Moll J; Moll J; Sysa A; Zeman K Przegl Lek; 2009; 66(7):359-64. PubMed ID: 20043576 [TBL] [Abstract][Full Text] [Related]
3. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury. Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226 [TBL] [Abstract][Full Text] [Related]
4. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211 [TBL] [Abstract][Full Text] [Related]
5. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes]. Florys B; Głowińska B; Urban M; Peczyńska J Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653 [TBL] [Abstract][Full Text] [Related]
6. [Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia]. Krawczuk-Rybak M; Kuźmicz M; Mroczko B; Szmitkowski M Pol Merkur Lekarski; 2010 Jul; 29(169):14-8. PubMed ID: 20712241 [TBL] [Abstract][Full Text] [Related]
7. Exercise ameliorates serum MMP-9 and TIMP-2 levels in patients with type 2 diabetes. Kadoglou NP; Vrabas IS; Sailer N; Kapelouzou A; Fotiadis G; Noussios G; Karayannacos PE; Angelopoulou N Diabetes Metab; 2010 Apr; 36(2):144-51. PubMed ID: 20149706 [TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443 [TBL] [Abstract][Full Text] [Related]
9. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis. Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230 [TBL] [Abstract][Full Text] [Related]
10. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis. Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412 [TBL] [Abstract][Full Text] [Related]
11. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip. Masuhara K; Nakai T; Yamaguchi K; Yamasaki S; Sasaguri Y Arthritis Rheum; 2002 Oct; 46(10):2625-31. PubMed ID: 12384920 [TBL] [Abstract][Full Text] [Related]
12. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401 [TBL] [Abstract][Full Text] [Related]
13. Circulating matrix metalloproteinases and their inhibitors in inguinal hernia and abdominal aortic aneurysm. Antoniou GA; Tentes IK; Antoniou SA; Georgiadis GS; Giannoukas AD; Simopoulos C; Lazarides MK Int Angiol; 2011 Apr; 30(2):123-9. PubMed ID: 21427648 [TBL] [Abstract][Full Text] [Related]
14. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441 [TBL] [Abstract][Full Text] [Related]
15. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835 [TBL] [Abstract][Full Text] [Related]
17. [Serum levels of matrix metaloproteinase 2 (MMP-2), matrix metaloproteinase 9 (MMP-9) and tissue inhibitor of metaloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency]. Szczepańska-Kostro J; Kowalewski M; Urban M; Gardziejczyk M Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(4):257-60. PubMed ID: 17239302 [TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173 [TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function. Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181 [TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]